John G. Flanagan

The paper identifies drug-induced lipoxins in glaucoma treatment, showing latanoprost increases lipoxin A4, which reduces inflammation and lowers intraocular pressure.

This study shows that Muller glia produce Lipoxin B4, which suppresses TRPV4-induced gliosis and neuroinflammation in ocular hypertension.

This study identifies LXB4's role in regulating microglia in the optic nerve during ocular hypertension, showing it reduces disease-associated microglia and promotes homeostasis.

This study investigates how the lipoxin pathway in astrocytes is dysregulated in response to cytokines and ocular hypertension, showing that LXB4 treatment mitigates astrocyte reactivity and restores lipoxin generation.

This study shows that exogenous LXA4 and LXB4 reduce inner retinal damage in a mouse glaucoma model, with LXB4 being more effective, and that LXA4 receptor deletion worsens injury.